Law
Offices of Howard G. Smith reminds investors that all purchasers of
the securities of STAAR Surgical Company (“STAAR” or the “Company”)
(NASDAQ:STAA) between February 27, 2013 and June 30, 2014, inclusive
(the “Class Period”),have until September 8, 2014, to file a motion to
be appointed as lead plaintiff in the shareholder lawsuit.
STAAR, together with its subsidiaries, designs, develops, manufactures
and sells implantable lenses for the eye and delivery systems to deliver
lenses into the eye. The Complaint alleges that STAAR’s Monrovia,
California, manufacturing facility was not in conformity with current
good manufacturing practice requirements because the facility: (1)
lacked adequate methodologies and facilities for the manufacture,
packing, storage and installation of the Company’s implantable lenses,
and (2) lacked adequate procedures for documenting complaints, sterility
testing and maintaining required records.
On June 30, 2014, the U.S. Food and Drug Administration released a
Warning Letter, dated May 21, 2014, concerning an inspection of STAAR’s
Monrovia facility from February 10, 2014 to March 21, 2014. The FDA
letter noted several regulatory violations at the facility and stated
that, among other things, “the methods used in, or the facilities or
controls used for” manufacture, packing, storage or installation of the
Company’s implantable lenses are “not in conformity with the current
good manufacturing practice requirements.”
If you are a member of the Class described above, you may move the Court
no later than September 8, 2014, to serve as lead plaintiff, if you meet
certain legal requirements. To be a member of the Class, you need not
take any action at this time; you may retain counsel of your choice or
take no action and remain an absent member of the Class. If you wish to
learn more about this action, please contact Howard G. Smith, Esquire,
of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free
at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com,
or visit our website at http://www.howardsmithlaw.com.
Copyright Business Wire 2014